Bortezomib induces methylation changes in neuroblastoma cells that appear to play a significant role in resistance development to this compound

Abstract The anticancer activity of bortezomib (BTZ) has been increasingly studied in a number of indications and promising results for the use of this treatment have been shown in neuroblastoma. As BTZ treatment is usually administered in cycles, the development of resistance and side effects in pa...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Karolina Łuczkowska, Katarzyna Ewa Sokolowska, Olga Taryma-Lesniak, Krzysztof Pastuszak, Anna Supernat, Jonas Bybjerg-Grauholm, Lise Lotte Hansen, Edyta Paczkowska, Tomasz K. Wojdacz, Bogusław Machaliński
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/f1af3d190e0e46aab864a91cdf1eba2b
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires